{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:08:28Z","timestamp":1792022908500,"version":"4.4.0"},"reference-count":192,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.msard.2020.102428","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T21:28:42Z","timestamp":1595971722000},"page":"102428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-5726","authenticated-orcid":false,"given":"Edgar","family":"Carnero Contentti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Daccach","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Flores-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-681X","authenticated-orcid":false,"given":"Marco","family":"Lana-Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Navas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Papais-Alvarenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-6020","authenticated-orcid":false,"given":"Douglas K.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibis","family":"Soto de Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Correale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102428_bib0001","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0002","article-title":"Epidemiology of neuromyelitis optica in Latin America","volume":"3","author":"Alvarenga","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2020.102428_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102045","article-title":"Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders","volume":"41","author":"Amaral","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102428_bib0004","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0005","article-title":"Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"4","author":"Asseyer","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2020.102428_bib0006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.msard.2018.12.010","article-title":"Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment","volume":"28","author":"Banerjee","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102428_bib0007","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2020.102428_bib0008","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102428_bib0009","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1471-2296-15-110","article-title":"Tools for measuring patient safety in primary care settings using the RAND\/UCLA appropriateness method","volume":"15","author":"Bell","year":"2014","journal-title":"BMC Fam. Pract."},{"issue":"6","key":"10.1016\/j.msard.2020.102428_bib0010","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1352458514567216","article-title":"Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography","volume":"21","author":"Bennett","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102428_bib0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1191\/1352458504ms988oa","article-title":"Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations","volume":"10","author":"Bergamaschi","year":"2004","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102428_bib0012","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2020.102428_bib0013","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1177\/1352458518776584","article-title":"Treating neuromyelitis optica with azathioprine: 20-year clinical practice","volume":"25","author":"Bichuetti","year":"2019","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2020.102428_bib0014","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/acr.23107","article-title":"Relationship between neuromyelitis optica spectrum disorder and Sj\u00f6gren\u2019s syndrome: central nervous system extraglandular disease or unrelated, co-occurring autoimmunity?","volume":"69","author":"Birnbaum","year":"2017","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.msard.2020.102428_bib0015","article-title":"Plasma exchange in severe attacks of neuromyelitis optica","volume":"2012","author":"Bonnan","year":"2012","journal-title":"Mult. Scler. Int."},{"issue":"4","key":"10.1016\/j.msard.2020.102428_bib0016","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0017","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s13167-018-0143-9","article-title":"Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies","volume":"9","author":"Borisow","year":"2018","journal-title":"EPMA J."},{"issue":"2","key":"10.1016\/j.msard.2020.102428_bib0018","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jcjo.2018.05.013","article-title":"Sensitivity of orbital magnetic resonance imaging in acute demyelinating optic neuritis","volume":"54","author":"Bursztyn","year":"2019","journal-title":"Can. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.msard.2020.102428_bib0019","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41393-018-0143-6","article-title":"Short-segment transverse myelitis lesions in a cohort of Latin American patients with neuromyelitis optica spectrum disorders","volume":"56","author":"Carnero Contentti","year":"2018","journal-title":"Spinal Cord."},{"key":"10.1016\/j.msard.2020.102428_bib0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.msard.2017.11.004","article-title":"Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: a cohort of Latin American patients","volume":"19","author":"Carnero Contentti","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2020.102428_bib0021","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s00415-020-09699-2","article-title":"Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort","volume":"267","author":"Carnero Contentti","year":"2020","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2020.102428_bib0022","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNO.0000000000000668","article-title":"Aquaporin-4 serostatus and visual outcomes in clinically isolated acute optic neuritis","volume":"39","author":"Carnero Contentti","year":"2019","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.msard.2020.102428_bib0023","article-title":"Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients [published online ahead of print, 2020 Jan 21]","author":"Carnero Contentti","year":"2020","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2020.102428_bib0024","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.nrl.2014.12.001","article-title":"Neuromyelitis optica: association with paroxysmal painful tonic spasms","volume":"31","author":"Carnero Contentti","year":"2016","journal-title":"Neurologia"},{"key":"10.1016\/j.msard.2020.102428_bib0025","article-title":"Brain and spinal MRI features distinguishing MS from different AQP4 antibody serostatus NMOSD at disease onset in a cohort of Latin American patients","author":"Carnero Contentti","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102428_bib0026","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.msard.2018.01.001","article-title":"Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients","volume":"20","author":"Carnero Contentti","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102428_bib0027","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2020.102428_bib0028","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1474-4422(18)30460-5","article-title":"Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"18","author":"Ciccarelli","year":"2019","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2020.102428_bib0029","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neurol.2017.11.005","article-title":"Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders","volume":"174","author":"Ciron","year":"2018","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.msard.2020.102428_bib0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","article-title":"Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study","volume":"373","author":"Cohen","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2020.102428_bib0031","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-018-1039-7","article-title":"Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options","volume":"79","author":"Collongues","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2020.102428_bib0032","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","volume":"22","author":"Collongues","year":"2016","journal-title":"Mult. Scler."},{"issue":"10076","key":"10.1016\/j.msard.2020.102428_bib0033","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","article-title":"Evolving concepts in the treatment of relapsing multiple sclerosis","volume":"389","author":"Comi","year":"2017","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.msard.2020.102428_bib0034","doi-asserted-by":"crossref","first-page":"e1183","DOI":"10.1212\/WNL.0000000000005256","article-title":"Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD","volume":"90","author":"Cortese","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102428_bib0035","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"issue":"10206","key":"10.1016\/j.msard.2020.102428_bib0036","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102428_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116609","article-title":"Consensus recommendations on the management of multiple sclerosis patients in Argentina","volume":"409","author":"Cristiano","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102428_bib0038","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2020.102428_bib0039","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/practneurol-2017-001788","article-title":"Neurocysticercosis: mimics and chameleons","volume":"19","author":"Delgado-Garc\u00eda","year":"2019","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0040","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.msard.2018.08.015","article-title":"Obstetric outcomes in a Mexican cohort of patients with AQP4-antibody seropositive neuromyelitis optica","volume":"25","author":"Delgado-Garc\u00eda","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102428_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101413","article-title":"Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia","volume":"36","author":"Drulovic","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102428_bib0042","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicenter retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102428_bib0043","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.msard.2020.102428_bib0044","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11910-014-0483-3","article-title":"Neuromyelitis optica spectrum disorders","volume":"14","author":"Flanagan","year":"2014","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0045","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1212\/CON.0000000000000742","article-title":"Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases","volume":"25","author":"Flanagan","year":"2019","journal-title":"Continuum (Minneap Minn)."},{"key":"10.1016\/j.msard.2020.102428_bib0046","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1007\/s00415-013-7031-y","article-title":"Neuromyelitis optica and pregnancy","volume":"260","author":"Fragoso","year":"2013","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0047","article-title":"Differential diagnosis of multiple sclerosis in Latin America","volume":"3","author":"Fragoso","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2020.102428_bib0048","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.msard.2018.11.031","article-title":"Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD)","volume":"27","author":"Fragoso","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2020.102428_bib0049","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1212\/NXI.0000000000000011","article-title":"AQP4 autoantibody assay performance in clinical laboratory service","volume":"1","author":"Fryer","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102428_bib0050","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/WNL.0b013e3182a6cc23","article-title":"AQP4 antibody serostatus: is its luster being lost in the management and pathogenesis of NMO?","volume":"81","author":"Fujihara","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0051","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3174\/ajnr.A6437","article-title":"SWAN-venule: an optimized MRI technique to detect the central vein sign in MS plaques","volume":"41","author":"Gait\u00e1n","year":"2020","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"1","key":"10.1016\/j.msard.2020.102428_bib0052","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.msard.2020.102428_bib0053","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrneurol.2018.14","article-title":"The current role of MRI in differentiating multiple sclerosis from its imaging mimics [published correction appears in Nat Rev Neurol. 2018 Mar 20;14 (4):213]","volume":"14","author":"Geraldes","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102428_bib0054","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00415-004-0271-0","article-title":"Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica","volume":"251","author":"Ghezzi","year":"2004","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0055","doi-asserted-by":"crossref","first-page":"d2651","DOI":"10.1136\/bmj.d2651","article-title":"Diagnosis and management of schistosomiasis","volume":"342","author":"Gray","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.msard.2020.102428_bib0056","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1352458516663853","article-title":"The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates","volume":"23","author":"Hamid","year":"2017","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2020.102428_bib0057","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0058","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol"},{"key":"10.1016\/j.msard.2020.102428_bib0059","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2018.02.022","article-title":"Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders","volume":"21","author":"Hu","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102428_bib0060","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3389\/fimmu.2018.02066","article-title":"Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in South China","volume":"9","author":"Huang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2020.102428_bib0061","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.msard.2019.08.009","article-title":"Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis","volume":"35","author":"Huang","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102428_bib0062","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jns.2016.11.054","article-title":"Pregnancy in neuromyelitis optica spectrum disorder: a multicenter study from South China","volume":"372","author":"Huang","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102428_bib0063","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0064","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/1352458516687043","article-title":"Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders","volume":"23","author":"Huh","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102428_bib0065","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/WNL.0000000000002655","article-title":"Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder","volume":"86","author":"Hyun","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2020.102428_bib0066","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3988\/jcn.2020.16.1.124","article-title":"Comparison of neuropathic pain in neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"16","author":"Hyun","year":"2020","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0067","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0068","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch. Neurol."},{"issue":"Pt 11","key":"10.1016\/j.msard.2020.102428_bib0069","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102428_bib0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J. Neuroinflammation."},{"issue":"1","key":"10.1016\/j.msard.2020.102428_bib0071","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflammation."},{"issue":"1-2","key":"10.1016\/j.msard.2020.102428_bib0072","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102428_bib0073","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.msard.2020.102428_bib0074","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol."},{"key":"10.1016\/j.msard.2020.102428_bib0075","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation."},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0076","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0077","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/practneurol-2017-001787","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations","volume":"19","author":"Jury\u0144czyk","year":"2019","journal-title":"Pract Neurol"},{"issue":"2","key":"10.1016\/j.msard.2020.102428_bib0078","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.msard.2020.102428_bib0079","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102428_bib0080","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2020.102428_bib0081","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167783","article-title":"Occurrence of asymptomatic acute neuromyelitis optica spectrum disorder-typical brain lesions during an attack of optic neuritis or myelitis","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS ONE"},{"issue":"14","key":"10.1016\/j.msard.2020.102428_bib0082","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1177\/1352458516687403","article-title":"Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders","volume":"23","author":"Kim","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102428_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2018.11.022","article-title":"Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder","volume":"130","author":"Kim","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.msard.2020.102428_bib0084","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.msard.2020.102428_bib0085","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1756285617709723","article-title":"Differential diagnosis of neuromyelitis optica spectrum disorders","volume":"10","author":"Kim","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"12","key":"10.1016\/j.msard.2020.102428_bib0086","doi-asserted-by":"crossref","first-page":"e82325","DOI":"10.1371\/journal.pone.0082325","article-title":"Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2020.102428_bib0087","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1007\/s00415-011-6086-x","article-title":"Cerebrospinal fluid\/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica","volume":"258","author":"Kim","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0088","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/WNL.0b013e318250d812","article-title":"Influence of pregnancy on neuromyelitis optica spectrum disorder","volume":"78","author":"Kim","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102428_bib0089","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/jcla.21508","article-title":"Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: comparison of tissue-based and cell-based indirect immunofluorescence assays and ELISA","volume":"26","author":"Kim","year":"2012","journal-title":"J. Clin. Lab. Anal."},{"issue":"4","key":"10.1016\/j.msard.2020.102428_bib0090","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102428_bib0091","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Nakashima I et\u00a0al Prognostic factors and disease course in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102428_bib0092","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1212\/WNL.0000000000004681","article-title":"High risk of postpartum relapses in neuromyelitis optica spectrum disorder","volume":"89","author":"Klawiter","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102428_bib0093","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm.."},{"key":"10.1016\/j.msard.2020.102428_bib0094","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jneuroim.2018.02.003","article-title":"Neuromyelitis optica spectrum disorder associated with dengue virus infection","volume":"318","author":"Lana-Peixoto","year":"2018","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2020.102428_bib0096","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines7020042","article-title":"Neuromyelitis optica spectrum disorder and anti-MOG syndromes","volume":"7","author":"Lana-Peixoto","year":"2019","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.msard.2020.102428_bib0097","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"issue":"9451","key":"10.1016\/j.msard.2020.102428_bib0098","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102428_bib0099","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fcimb.2017.00449","article-title":"Neurological manifestations of dengue infection","volume":"7","author":"Li","year":"2017","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"9","key":"10.1016\/j.msard.2020.102428_bib0100","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/1352458512471875","article-title":"Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders","volume":"19","author":"Lim","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102428_bib0101","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.msard.2017.07.004","article-title":"Painful tonic spasm in neuromyelitis optica spectrum disorders: prevalence, clinical implications and treatment options","volume":"17","author":"Liu","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102428_bib0102","article-title":"Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders","volume":"39","author":"Lotan","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2020.102428_bib0103","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archneurol.2011.34","article-title":"Beneficial plasma exchange response in central nervous system inflammatory demyelination","volume":"68","author":"Maga\u00f1a","year":"2011","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0104","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102428_bib0105","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102428_bib0106","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-020-0313-y","article-title":"Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations","author":"Mao-Draayer","year":"2020","journal-title":"Nat Rev Neurol."},{"issue":"6","key":"10.1016\/j.msard.2020.102428_bib0107","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1212\/NXI.0000000000000498","article-title":"Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders","volume":"5","author":"Marcinn\u00f2","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102428_bib0108","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","article-title":"Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity dependent entity","volume":"80","author":"Marignier","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102428_bib0109","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0110","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000303817.82134.da","article-title":"NMO-IgG predicts the outcome of recurrent optic neuritis","volume":"70","author":"Matiello","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102428_bib0111","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.0b013e3182887957","article-title":"Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution","volume":"80","author":"Matthews","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2020.102428_bib0112","article-title":"Updated diagnostic criteria for neuromyelitis optica spectrum disorder: similar outcomes of previously separate cohorts","volume":"4","author":"McCreary","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"4","key":"10.1016\/j.msard.2020.102428_bib0113","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0284185112471797","article-title":"Accuracy of routine fat-suppressed FLAIR and diffusion-weighted images in detecting clinically evident acute optic neuritis","volume":"54","author":"McKinney","year":"2013","journal-title":"Acta Radiol."},{"issue":"4","key":"10.1016\/j.msard.2020.102428_bib0114","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm.."},{"key":"10.1016\/j.msard.2020.102428_bib0115","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102428_bib0116","first-page":"172","article-title":"Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica","volume":"35","author":"Mok","year":"2008","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.msard.2020.102428_bib0117","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Mult. Scler."},{"issue":"13","key":"10.1016\/j.msard.2020.102428_bib0118","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3109\/09638288.2013.833301","article-title":"Life on hold: the experience of living with neuromyelitis optica","volume":"36","author":"Mutch","year":"2014","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.msard.2020.102428_bib0119","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","article-title":"Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes","volume":"82","author":"Nagaishi","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.msard.2020.102428_bib0120","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","article-title":"Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels","volume":"18","author":"Nakashima","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2020.102428_bib0121","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102428_bib0122","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0123","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s10047-018-1044-3","article-title":"Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level","volume":"21","author":"Nishimura","year":"2018","journal-title":"J. Artif. Organs"},{"key":"10.1016\/j.msard.2020.102428_bib0124","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1212\/WNL.0000000000002208","article-title":"Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"86","author":"Nour","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2020.102428_bib0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s13167-017-0123-5","article-title":"Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy","volume":"9","author":"Oertel","year":"2017","journal-title":"EPMA J."},{"issue":"4","key":"10.1016\/j.msard.2020.102428_bib0126","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/practneurol-2012-000237","article-title":"A practical guide to the treatment of neuromyelitis optica","volume":"12","author":"Palace","year":"2012","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0127","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2020.102428_bib0128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/archophthalmol.2007.26","article-title":"Clinical course of optic neuritis in patients with relapsing neuromyelitis optica","volume":"126","author":"Papais-Alvarenga","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.msard.2020.102428_bib0129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.msard.2018.07.026","article-title":"Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: an ethnicity influence?","volume":"25","author":"Papais-Alvarenga","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2020.102428_bib0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127757","article-title":"Central nervous system idiopathic inflammatory demyelinating disorders in South Americans: a descriptive, multicenter, cross-sectional study","volume":"10","author":"Papais-Alvarenga","year":"2015","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.msard.2020.102428_bib0131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127757","article-title":"Central nervous system idiopathic inflammatory demyelinating disorders in South Americans: a descriptive, multicenter, cross-sectional study","volume":"10","author":"Papais-Alvarenga","year":"2015","journal-title":"PLoS ONE"},{"issue":"15","key":"10.1016\/j.msard.2020.102428_bib0132","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102428_bib0133","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2020.102428_bib0134","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrneurol.2014.108","article-title":"The investigation of acute optic neuritis: a review and proposed protocol [published correction appears in Nat Rev Neurol. 2014 Aug;10(8):i]","volume":"10","author":"Petzold","year":"2014","journal-title":"Nat Rev Neurol."},{"issue":"7","key":"10.1016\/j.msard.2020.102428_bib0135","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2020.102428_bib0136","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non-organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0137","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0138","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fneur.2019.01028","article-title":"AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD","volume":"10","author":"Prain","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0139","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jocn.2015.01.028","article-title":"Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica","volume":"22","author":"Qiu","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2020.102428_bib0140","unstructured":"Rand Corporation. The RAND\/UCLA appropriateness method user's manual. Santa Monica: RAND; 2001. Development of Good Practice Guidelines. \u2018\u2018Formal Consensus\u2019\u2019 Method. December 2010, updated March2015.https:\/\/www.hassante.fr\/portail\/upload\/docs\/application\/pdf\/201803\/good_practice_guidelines_fc_method.pdf."},{"issue":"2","key":"10.1016\/j.msard.2020.102428_bib0141","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102428_bib0142","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0143","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102428_bib0144","first-page":"4","article-title":"Neuromyelitis optica (NMO IgG+) and genetic susceptibility, potential ethnic influences","volume":"18","author":"Rivas-Alonso","year":"2018","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.msard.2020.102428_bib0145","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00415-008-0781-2","article-title":"Characteristics of devic's disease (neuromyelitis optica) in Mexico","volume":"255","author":"Rivera","year":"2008","journal-title":"J Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0146","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.msard.2019.05.007","article-title":"Neuromyelitis optica and pregnancy-puerperal cycle","volume":"34","author":"Salvador","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2020.102428_bib0147","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.transproceed.2008.05.018","article-title":"Application of the RAND\/UCLA appropriateness method to evaluate an information system for kidney\/pancreas transplantation in adult recipients","volume":"40","author":"Santori","year":"2008","journal-title":"Transplant. Proc."},{"issue":"12","key":"10.1016\/j.msard.2020.102428_bib0148","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrneurol.2016.166","article-title":"The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative","volume":"12","author":"Sati","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2020.102428_bib0149","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2020.102428_bib0150","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1590\/0004-282X20140032","article-title":"Seronegative neuromyelitis optica spectrum\u2014the challenges on disease definition and pathogenesis","volume":"72","author":"Sato","year":"2014","journal-title":"Arq. Neuropsiquiatr."},{"issue":"8","key":"10.1016\/j.msard.2020.102428_bib0151","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0152","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jns.2016.06.030","article-title":"Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder","volume":"368","author":"Seok","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102428_bib0153","article-title":"Efficacy and safety of satralizumab for relapse prevention in neuromyelitis optica spectrum disorder: a pooled analysis from two phase 3 clinical trials","volume":"37","author":"Seze","year":"2020","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0154","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-019-09180-9","article-title":"Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study","volume":"266","author":"Shaygannejad","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0155","article-title":"Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study","author":"Shi","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0156","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1177\/1352458515583376","article-title":"Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder","volume":"22","author":"Shimizu","year":"2016","journal-title":"Mult. Scler."},{"issue":"14","key":"10.1016\/j.msard.2020.102428_bib0157","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1177\/1352458517740215","article-title":"Neuromyelitis optica spectrum disorders and pregnancy: interactions and management","volume":"23","author":"Shosha","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102428_bib0158","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102049","article-title":"Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population","volume":"42","author":"Silveira","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2020.102428_bib0159","article-title":"Evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis [published online ahead of print, 2019 Aug 19]","volume":"76","author":"Sinnecker","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0160","article-title":"A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX","volume":"38","author":"Songthammawat","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102428_bib0161","article-title":"Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning [published online ahead of print, 2019 Jul 31]","author":"Sotirchos","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102428_bib0162","series-title":"Presented at the 11th International NMO Roundtable Conference","article-title":"Neuromyelitis optica spectrum disorders: epidemiologic study in Venezuela","author":"Soto de Castillo","year":"2019"},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0163","article-title":"Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis","volume":"4","author":"Srikajon","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2020.102428_bib0164","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2020.102428_bib0165","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm.."},{"key":"10.1016\/j.msard.2020.102428_bib0166","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2020.102428_bib0167","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0168","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","article-title":"Analysis of the treatment of neuromyelitis optica","volume":"351","author":"Torres","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2020.102428_bib0169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2020.102428_bib0170","doi-asserted-by":"crossref","first-page":"e39372","DOI":"10.1371\/journal.pone.0039372","article-title":"Aquaporin-4 antibodies are not related to HTLV-1 associated myelopathy","volume":"7","author":"von Glehn","year":"2012","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.msard.2020.102428_bib0171","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102428_bib0172","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102428_bib0173","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2020.102428_bib0174","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/cen3.12107","article-title":"Evaluation of aquaporin-4 antibody assays","volume":"5","author":"Waters","year":"2014","journal-title":"Clin. Exp. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.msard.2020.102428_bib0175","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0176","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"Weinshenker","year":"2006","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2020.102428_bib0177","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"7","key":"10.1016\/j.msard.2020.102428_bib0178","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","article-title":"Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease)","volume":"63","author":"Weinstock-Guttman","year":"2006","journal-title":"Arch. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2020.102428_bib0179","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1007\/s00415-017-8445-8","article-title":"What's new in neuromyelitis optica? A short review for the clinical neurologist","volume":"264","author":"Whittam","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0180","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102428_bib0181","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102428_bib0182","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102428_bib0183","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","article-title":"clinical predictors of a relapsing course and survival","volume":"60","author":"Wingerchuk","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2020.102428_bib0184","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102428_bib0185","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2020.102428_bib0186","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.msard.2020.102428_bib0187","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102428_bib0188","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2020.102428_bib0189","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"issue":"12","key":"10.1016\/j.msard.2020.102428_bib0190","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.5588\/ijtld.10.0780","article-title":"Neuromyelitis optica and pulmonary tuberculosis: a case-control study","volume":"15","author":"Zatjirua","year":"2011","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.msard.2020.102428_bib0191","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Zephir","year":"2015","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2020.102428_bib0192","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."}],"updated-by":[{"DOI":"10.1016\/j.msard.2021.103026","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000}}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:50:02Z","timestamp":1761900602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820305034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":192,"alternative-id":["S2211034820305034"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102428","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102428","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102428"}}